A Single-Dose Pharmacokinetic Study of Lepodisiran in Participants with Varying Degrees of Liver Impairment and Participants with Normal Liver Function

2024-520315-40-00 Protocol J3L-MC-EZEH Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 22 Jul 2025 · Status Ongoing, recruitment ended · 1 EU/EEA countries · 1 sites · Protocol J3L-MC-EZEH

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 33
Countries 1
Sites 1

Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment

Key facts

Sponsor
Eli Lilly & Co.
Participant type
Patients, Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Digestive System Diseases [C06]
Trial duration
22 Jul 2025 → ongoing
Decision date (initial)
2025-06-16
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-520315-40-00
WHO UTN
U1111-1316-8745

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment

VersionLevelCodeTermSystem organ class
22.1 LLT 10052254 Hepatic impairment 10019805

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Eli Lilly & Co.

Sponsor organisation
Eli Lilly & Co.
Address
1 Lilly Corporate Center
City
Indianapolis
Postcode
46285-0001
Country
United States

Scientific contact point

Organisation
Eli Lilly & Co.
Contact name
Lilly Clinical Trials information desk

Public contact point

Organisation
Eli Lilly & Co.
Contact name
Lilly Clinical Trials information desk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ongoing, recruitment ended 6 1
Rest of world
Singapore, United States
27

Investigational sites

Hungary

1 site · Ongoing, recruitment ended
CRU Hungary Kft.
NA, Semmelweis Ter 1, 2143, Kistarcsa

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2025-07-22 2025-08-11 2026-05-13

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-04-07 Hungary Acceptable
2025-06-03
2025-06-16
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-03-13 Hungary Acceptable
2025-06-03
2026-03-13
3 NON SUBSTANTIAL MODIFICATION NSM-2 2026-03-16 Hungary Acceptable
2025-06-03
2026-03-16